<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912441</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-147-1</org_study_id>
    <nct_id>NCT03912441</nct_id>
  </id_info>
  <brief_title>First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects</brief_title>
  <official_title>Open-label Non-Comparator Multicohort Trial of Pharmacokinetics, Safety And Immunogenicity of BCD-147 (JSC &quot;BIOCAD&quot;, Russia) After Single Administration of Escalating Doses in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase 1, &quot;3+3 trial&quot; of pharmacokinetics, safety and immunogenicity of
      BCD-147 (JSC &quot;BIOCAD&quot;, Russia) after single administration of escalating doses in healthy
      male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of volunteers with treatment-emerged adverse events of any grade per NCI CTCAE 5.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of volunteers with treatment-emerged adverse events of grade 3 and higher per NCI CTCAE 5.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of volunteers with both binding and neutralizing antibodies</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BCD-147 Monotherapy Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-147 Monotherapy Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-147 Monotherapy Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-147 Monotherapy Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-147</intervention_name>
    <description>Bispecific anti-HER2 monoclonal antibody</description>
    <arm_group_label>BCD-147 Monotherapy Dose Level 1</arm_group_label>
    <arm_group_label>BCD-147 Monotherapy Dose Level 2</arm_group_label>
    <arm_group_label>BCD-147 Monotherapy Dose Level 3</arm_group_label>
    <arm_group_label>BCD-147 Monotherapy Dose Level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form and the subject's ability to follow the Protocol
             requirements;

          2. Male gender 18-45 years of age inclusively at the signing of the informed consent;

          3. Body mass index (BMI) in the normal range (18.0 - 30.0 kg / sq.m.);

          4. Left ventricular ejection fraction is at least 55% measured by echocardiography;

          5. Volunteer's ability to follow Protocol's procedures;

          6. Verified diagnosis: &quot;Healthy&quot; according to standard clinical, laboratory, and
             instrumental examination methods;

          7. Hemodynamic parameters within the normal range: systolic blood pressure (BP) in the
             range of 90-130 mm Hg., diastolic blood pressure in the range of 60-90 mm Hg., heart
             rate - 60-90 beats / min;

          8. Consent of volunteers and their sexual partners with childbearing potential to use
             adequate contraception throughout the entire trial period. This includes the use of
             the 1st barrier method in combination with one of the following: spermicides,
             intrauterine device / oral contraceptives;

          9. Volunteer's ability not to drink alcohol within 24 hours prior to the administration
             of the drug and throughout the entire trial period.

        Exclusion Criteria:

          1. Participation in any other clinical trial within 30 days before the signing of the
             informed consent for this clinical trial;

          2. Any condition that prevents a patient from following the Protocol procedures
             (dementia, neurological or mental disorders, drug/alcohol abuse, etc.);

          3. The inability of venous puncture for the collection of blood samples (e.g., due to
             skin diseases);

          4. Any surgical procedures that have been transferred within less than 28 days before the
             signing of the informed consent or planned within 28 days after completion of study
             participation;

          5. Presence of any disorders that, according to the researcher, may affect the
             pharmacokinetics and safety of the investigational drug;

          6. HBV/HCV/HIV infection, active syphilis;

          7. Acute infection or the acute phase of chronic infection within 28 days prior the first
             dose of the investigational product; Active HBV/HCV/HIV infection, active syphilis;

          8. Values of standard laboratory and instrumental indicators that go beyond the limits of
             laboratory standards adopted in the central laboratory;

          9. Use of medicines that have a pronounced effect on hemodynamics, liver function, etc.
             (barbiturates, omeprazole, cimetidine, etc.) less than 28 days before the signing of
             informed consent and / or the need to take any medications throughout the entire study
             (except for the study drug);

         10. Regular use and parenteral administration of any drugs, including non-prescription
             drugs, vitamins and dietary supplements, less than 14 calendar days before the signing
             of informed consent;

         11. Known severe allergy (anaphylaxis or multidrug intolerance);

         12. Hypersensitivity to any of the components of BCD-147;

         13. Smoking of more than 10 cigarettes per day;

         14. Use of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to Â½
             liter of beer, 200 ml of wine or 50 ml of spirits) or anamnestic information about
             alcoholism, drug addiction or drug abuse, or positive tests for alcohol and / or
             psychotropic / narcotic substances during the screening visit;

         15. Donation of 450 ml or more of blood or plasma within 60 calendar days prior to the
             signing of informed consent;

         16. Cardiovascular disorders, including hypertension or hypotension;

         17. Edema of the lower limbs within 14 days before the signing of the informed consent;

         18. A history of clinically significant systemic diseases;

         19. Use of intravenous antibiotics within 7 days before the signing of informed consent.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman A Ivanov</last_name>
    <role>Study Director</role>
    <affiliation>Vice President R&amp;D, JSC BIOCAD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariia S Shustova, MD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivan K Alvovskii</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Center &quot;Eco-Safety&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin A Zakharov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

